BIOTECH ASSISTANT / FIELD NOTES

ARO-DIMER-PA shows dual lipid lowering in early human study, with dose-related safety findings

Company / institutional announcement · Arrowhead Pharmaceuticals

Source published: 2026-11-07 · Event / reporting date: 2026-11-07

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Arrowhead reported Phase 1/2a interim data involving 21 ARO-DIMER-PA recipients and 10 placebo recipients. Across dose cohorts, mean LDL-C fell 26%–65% and median triglycerides fell 56%–78% from baseline; these were not placebo-adjusted effects. Injection-site erythema occurred in 20 treated participants, and one participant receiving 400 mg experienced Grade 3 syncope. Cardiovascular outcome benefit remains unestablished.

Why it may matter

Potential business implication: dual-target RNAi may broaden lipid-management development opportunities, but dose selection and longer safety follow-up remain central requirements.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Pharmaron Alnylam Pharmaceuticals Ionis Pharmaceuticals Wave Life Sciences Arrowhead Pharmaceuticals

Explore field companies →Explore literature →

Related updates

2026-11-07Cleveland Clinic

Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction

Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.

Oligonucleotide Therapeutics & Delivery Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-06Phio Pharmaceuticals

Phio schedules final PH-762 Phase 1b findings and plans Phase 2b in 2027

Phio announced a November 7 SITC oral presentation of final Phase 1b findings for intratumoral PH-762, its PD-1-silencing siRNA candidate, in cutaneous carcinomas. The company described tolerability and potential tissue-sparing neoadjuvant use, while stating that additional safety and efficacy studies are needed. A Phase 2b study is planned for the first half of 2027.

Oligonucleotide Therapeutics & Delivery Ask AI ↗

2026-11-06Vir Biotechnology / Business Wire

Vir schedules Phase 3 elebsiran–tobevibart results for The Liver Meeting

Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.

Oligonucleotide Therapeutics & Delivery Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗